Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …

Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by
enhancing antigen presentation to antigen-specific immune cells with the aim to confer long …

Background The efficacy and safety of the RTS, S/AS01 candidate malaria vaccine during
18 months of follow-up have been published previously. Herein, we report the final results …

Vaccines containing novel adjuvant formulations are increasingly reaching advanced
development and licensing stages, providing new tools to fill previously unmet clinical …

For decades infections have been treated easily with drugs. However, in the 21st century,
they may become lethal again owing to the development of antimicrobial resistance …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Adjuvants are substances added to vaccines to improve their immunogenicity. Used for
more than 80 years, aluminum, the first adjuvant in human vaccines, proved insufficient to …

Malaria is a parasitic infection caused by bites from Plasmodium falciparum (P. falciparum)-
infected mosquitoes with a present scale of symptoms ranging from moderate fever to …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …